Prescription medicine
Metoprolol Brand names: Toprol, Kapspargo, Lopressor
Metoprolol (Lopressor) is a prescription medicine with an FDA approval on record since 1978. FDA's NDC Directory lists it from 74 generic labelers, and pharmacies paid $0.085 per metoprolol succ ER 100 mg tablet in the October 7, 2026 NADAC survey; its other strengths are brand-only, $1.20 per mL (Lopressor 10 mg/mL oral solution).
- Generic listed
- A presentation discontinued
Check it at the source: the metoprolol FDA label on DailyMed (effective March 3, 2026, Melinta Therapeutics, LLC); the NDA 17963 record on Drugs@FDA; every metoprolol label on DailyMed.
Highlights of the record
FDA label of March 3, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageTOPROL-XL, metoprolol succinate, is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure.
Forms and strengths
- 12.5 mg
- 25 mg
- 37.5 mg
- 50 mg
- 75 mg
- 100 mg
- 200 mg
- 1 mg/ml
- 5 mg/5ml
- 10 mg/ml
Extended-release tablet; film-coated tablet; film-coated extended-release tablet; tablet; injection (solution).
On the market
- Earliest approval on file
- August 7, 1978 Lopressor, Validus Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 60 first December 21, 1993; 33 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 78 of which 74 under generic applications, 5 under brand applications, repackagers included
- Last listed patent
- July 9, 2035 Kapspargo Sprinkle capsules; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.085 per tablet Metoprolol succ ER 100 mg tablet
- Shortage (FDA)
- None current 7 past records
- Recalls by its makers (FDA)
- 39 since 2012 0 Class I among all firms' recalls; latest April 27, 2026; 1 more by firms not listed as its makers
- FAERS reports
- 353,609 through July 30, 2026
What is metoprolol used for?
From the label: indications and usageTOPROL-XL, metoprolol succinate, is a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure ( 1.3 ) 1.1 Hypertension TOPROL-XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. […]
Conditions named in the indications of metoprolol's FDA labels, with every medicine labeled for each:
From other metoprolol labelsAngina: Angina Pectoris TOPROL-XL is indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance.
Heart failure: Heart Failure TOPROL-XL is indicated to reduce the risk of cardiovascular mortality and heart-failure hospitalization in patients with heart failure.
Heart attack and coronary artery disease: Metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous …
FDA pharmacologic class: beta-Adrenergic Blocker.
Source: FDA drug label (TOPROL XL), Melinta Therapeutics, LLC, effective March 3, 2026 (SPL set 496ddfaa-7c9c-4888-b747-a210249b367a), via openFDA; the full label on DailyMed
Is there a generic for metoprolol (Lopressor)?
The FDA approved the first generic metoprolol on December 21, 1993. 60 generic applications are approved; 33 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists metoprolol from 74 labelers under a generic (ANDA) application and from 5 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Lopressor tablets; a patent listed only for Kapspargo Sprinkle capsules runs to July 9, 2035. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1978 earliest approval on file
- 1993 first generic approved
- 2035 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for metoprolol (Lopressor)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.085 per Metoprolol succ ER 100 mg tablet, down 8% from $0.0924 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Metoprolol succ ER 100 mg tablet (generic)
- Lopressor 10 mg/mL oral solution (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Metoprolol succ ER 100 mg tablet | Generic | $0.085 per tablet | $2.55 | -8% |
| Metoprolol succ ER 200 mg tablet | Generic | $0.188 per tablet | $5.64 | +18% |
| Metoprolol succ ER 25 mg tablet | Generic | $0.0476 per tablet | $1.43 | -16% |
| Metoprolol succ ER 50 mg tablet | Generic | $0.0515 per tablet | $1.55 | -19% |
| Metoprolol tartrate 100 mg tablet | Generic | $0.0287 per tablet | $0.860 | +9% |
| Metoprolol tartrate 12.5 mg tablet | Generic | $2.87 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $86.23 | n/a |
| Metoprolol tartrate 25 mg tablet | Generic | $0.0159 per tablet | $0.476 | -8% |
| Metoprolol tartrate 37.5 mg tablet | Generic | $0.0759 per tablet | $2.28 | +3% |
| Metoprolol tartrate 50 mg tablet | Generic | $0.0195 per tablet | $0.585 | -12% |
| Metoprolol tartrate 75 mg tablet | Generic | $0.154 per tablet | $4.62 | +16% |
| Kapspargo sprinkle 100 mg capsule | Brand | $2.29 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $68.78 | +4% |
| Kapspargo sprinkle 25 mg capsule | Brand | $1.89 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $56.63 | +2% |
| Kapspargo sprinkle 50 mg capsule | Brand | $1.89 per capsule many times the lowest per-tablet cost; NADAC records the price, not why | $56.62 | +2% |
| Lopressor 10 mg/mL oral solution | Brand | $1.20 per mL | n/a | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is metoprolol in shortage?
No metoprolol presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 7 records are all marked to be discontinued, the latest updated August 31, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-11) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | August 31, 2026 |
| Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-96) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | August 31, 2026 |
| Metoprolol Succinate, Tablet, Extended Release, 200 mg (NDC 45963-678-11) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | August 31, 2026 |
| Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-11) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | August 31, 2026 |
| Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-96) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | August 31, 2026 |
| Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-11) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | August 31, 2026 |
| Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-96) | Teva Pharmaceuticals USA, Inc. | To Be Discontinued | August 31, 2026 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has metoprolol been recalled?
The FDA's Enforcement Report lists 40 recalls naming metoprolol since 2012: 0 Class I (the most serious), 38 Class II, 2 Class III; 9 still ongoing. 1 of them is by a firm that FDA's NDC Directory does not list as a maker of metoprolol and that holds no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| April 27, 2026 | Class II | Ascend Laboratories, LLC | Failed Dissolution Specifications |
| January 29, 2026 | Class II | Teva Pharmaceuticals USA, Inc | Failed Dissolution Specifications |
| August 6, 2025 | Class II | Westminster Pharmaceuticals LLC | CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level. |
| June 24, 2025 | Class II | Granules Pharmaceuticals Inc. | Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25°C/60% RH) long-term. |
| May 6, 2024 | Class II | Rubicon Research Private Limited | Presence of Foreign Substance: metal in tablet |
| January 11, 2023 | Class II | Amerisource Health Services LLC | Failed Dissolution Specifications: This recall is being initiated in support of the recall by the manufacturer which included lots that were packaged for … |
| January 5, 2023 | Class II | Ascend Laboratories, LLC | Failed Dissolution Specification |
| April 13, 2022 | Class II | Mckesson Medical-Surgical Inc. Corporate Office | cGMP deviations: Temperature abuse |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the metoprolol label say about other medicines?
The metoprolol label names 8 other medicines in its interaction, contraindication or warning sections. The labels of 36 other medicines name metoprolol. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Clonidine | drug interactions | DRUG INTERACTIONS Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7.1 ) CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7.2 ) Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. |
| Diltiazem | drug interactions | Digitalis glycosides, clonidine, diltiazem, and verapamil slow atrioventricular conduction and decrease heart rate. |
| Epinephrine | warnings and precautions | Can aggravate symptoms of arterial insufficiency. ( 5.9 ) Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. |
| Fluoxetine | drug interactions | Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. |
| Paroxetine | drug interactions | Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. |
| Propafenone | drug interactions | Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. |
| Quinidine | drug interactions | Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. |
| Verapamil | drug interactions | Digitalis glycosides, clonidine, diltiazem, and verapamil slow atrioventricular conduction and decrease heart rate. |
Other labels that name metoprolol
Source: FDA drug label (TOPROL XL), Melinta Therapeutics, LLC, effective March 3, 2026 (SPL set 496ddfaa-7c9c-4888-b747-a210249b367a), via openFDA; the full label on DailyMed
What do FAERS reports show for metoprolol?
The FDA Adverse Event Reporting System holds 353,609 reports that list metoprolol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 38,371 are coded as a death and 136,050 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as metoprolol?
80 other medicines are given the same way (oral) and in the same FDA class as metoprolol or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Propranolol | High blood pressure, Angina | 38 labelers | $0.0493 per tablet 20 mg tablet | In shortage |
| Carvedilol | High blood pressure, Heart failure | 41 labelers | $0.0179 per tablet 6.25 mg tablet | No current entry |
| Atenolol | High blood pressure, Angina, Heart attack and coronary artery disease | 35 labelers | $0.0217 per tablet 25 mg tablet | No current entry |
| Labetalol | High blood pressure | 31 labelers | $0.215 per tablet 300 mg tablet | No current entry |
| Nebivolol | High blood pressure | 23 labelers | $0.141 per tablet 10 mg tablet | A presentation being discontinued |
| Nadolol | High blood pressure, Angina | 16 labelers | $0.147 per tablet 20 mg tablet | No current entry |
| Bisoprolol | High blood pressure | 24 labelers | $0.114 per tablet 5 mg tablet | No current entry |
| Bisoprolol and hydrochlorothiazide | High blood pressure | 11 labelers | $0.209 per tablet 10-6.25 mg tablet | No current entry |
Every medicine labeled for the same conditions as metoprolol
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does metoprolol compare with medicines for the same use?
32 side-by-side pages set metoprolol beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
- Acebutolol
- Amlodipine
- Atenolol
- Atorvastatin
- Bisoprolol
- Candesartan
- Captopril
- Carvedilol
- Chlorthalidone
- Clonidine
- Digoxin
- Diltiazem
- Enalapril
- Esmolol
- Hydrochlorothiazide
- Irbesartan
- Ivabradine
- Labetalol
- Lisinopril
- Losartan
- Nadolol
- Nebivolol
- Nifedipine
- Olmesartan
- Pindolol
- Prazosin
- Propranolol
- Ramipril
- Spironolactone
- Telmisartan
- Valsartan
- Verapamil
What next?
- Alternatives to metoprolol
- 80 medicines for the same use
- Other beta blockers
- the pharmacologic class, with prices and generics
- Metoprolol side effects
- the label's list beside FAERS reports
- Metoprolol shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other